Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Go back to Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting| (NASDAQ: FHTX) | Delayed: 4.22 +0.07 (1.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.15 | 52 Week High | $ | |||
| Open | $4.20 | 52 Week Low | $ | |||
| Day High | $4.27 | P/E | N/A | |||
| Day Low | $4.14 | EPS | $ | |||
| Volume | 20,293 | |||||
